In a court session on Friday (09), witness testimonies shed light on a nurse who is presently undergoing trial for the alleged murder of seven babies at a UK hospital. The testimonies depicted her as a "very calculating woman" who was deemed responsible for the tragic deaths of "many children".
Lucy Letby, aged 33, faces additional charges of allegedly attempting to cause harm to 10 other babies in the neo-natal unit of the Countess of Chester Hospital located in northwest England where she was employed.
However, Letby firmly refuted the accusations of harming any children.
"You are a murderer... You have murdered many children," prosecutor Nick Johnson said in an exchange with Letby on the final day of her cross-examination at the Manchester Crown Court.
"I have never murdered a child or harmed any of them," she replied.
Letby stands accused of deliberately harming newborns through various methods between June 2015 and June 2016, which allegedly included administering injections of insulin, air, or milk.
After being removed from the neo-natal unit in July 2016, she continued her employment at the hospital, albeit in clerical roles, until her arrest two years later.
During the court proceedings, Letby expressed a sense of "isolation" following her transfer from the unit and claimed that she was only permitted to communicate with a limited number of colleagues.
Prosecutor Johnson said Friday that Letby's social diary at the time was "peppered with you out socialising with lots of different people on that unit".
Letby agreed with his assertion that she had a "very active social life".
"You are a calculating woman aren't you Miss Letby? You tell lies deliberately, don't you?" Johnson continued.
He said Letby lied "to get sympathy from people" and "to get attention from people".
Letby replied to his questions with a simple "no".
During her testimony in the witness box last month, Letby revealed her longstanding desire to work with children and expressed deep distress upon learning that she was being accused of causing the deaths of the babies.
The charges against Letby include seven counts of murder and 15 counts of attempted murder, as she is alleged to have made multiple attempts to harm certain children.
The trial, which has been ongoing since October, will continue next week.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.